PT1490066E - Utilização de ranolazina para a preparação de um medicamento para o tratamento de arritmias - Google Patents

Utilização de ranolazina para a preparação de um medicamento para o tratamento de arritmias Download PDF

Info

Publication number
PT1490066E
PT1490066E PT03723907T PT03723907T PT1490066E PT 1490066 E PT1490066 E PT 1490066E PT 03723907 T PT03723907 T PT 03723907T PT 03723907 T PT03723907 T PT 03723907T PT 1490066 E PT1490066 E PT 1490066E
Authority
PT
Portugal
Prior art keywords
ranolazine
arrhythmias
medicament
preparation
treatment
Prior art date
Application number
PT03723907T
Other languages
English (en)
Inventor
Luiz Belardinelli
Antzelevitch Charles
Brent Blackburn
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Publication of PT1490066E publication Critical patent/PT1490066E/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PT03723907T 2002-04-04 2003-04-04 Utilização de ranolazina para a preparação de um medicamento para o tratamento de arritmias PT1490066E (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37015002P 2002-04-04 2002-04-04
US40829202P 2002-09-05 2002-09-05
US42258902P 2002-10-30 2002-10-30

Publications (1)

Publication Number Publication Date
PT1490066E true PT1490066E (pt) 2008-07-22

Family

ID=29255318

Family Applications (2)

Application Number Title Priority Date Filing Date
PT03723907T PT1490066E (pt) 2002-04-04 2003-04-04 Utilização de ranolazina para a preparação de um medicamento para o tratamento de arritmias
PT08004276T PT1930007E (pt) 2002-04-04 2003-04-04 Utilização de ranolazina para a preparação de um medicamento para o tratamento de pós-despolarizações precoces (ead)

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT08004276T PT1930007E (pt) 2002-04-04 2003-04-04 Utilização de ranolazina para a preparação de um medicamento para o tratamento de pós-despolarizações precoces (ead)

Country Status (20)

Country Link
US (2) US20030220344A1 (pt)
EP (3) EP2198866A1 (pt)
JP (1) JP4608217B2 (pt)
KR (2) KR20100119804A (pt)
CN (2) CN101843619A (pt)
AT (2) ATE397932T1 (pt)
AU (3) AU2003230810B2 (pt)
CA (1) CA2481192C (pt)
CY (1) CY1110400T1 (pt)
DE (2) DE60332975D1 (pt)
DK (2) DK1490066T3 (pt)
ES (2) ES2304507T3 (pt)
HK (1) HK1120390A1 (pt)
IL (1) IL197406A0 (pt)
MX (1) MXPA04009637A (pt)
NO (1) NO330953B1 (pt)
NZ (1) NZ535610A (pt)
PT (2) PT1490066E (pt)
SI (2) SI1490066T1 (pt)
WO (1) WO2003086401A1 (pt)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030220344A1 (en) * 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias
CA2486712C (en) * 2002-05-21 2012-01-03 Cv Therapeutics, Inc. Method of treating diabetes
US8822473B2 (en) * 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
EP1723129A1 (en) * 2003-12-18 2006-11-22 Cv Therapeutics, Inc. 1-akan-2-ol substituted piperazine and piperidine compounds
SG156681A1 (en) * 2004-11-09 2009-11-26 Cv Therapeutics Inc Use of ranolazine in combination with at least one remodeling agent for reversing left ventricular remodeling in the treatment of heart failure
KR20070093988A (ko) * 2005-01-06 2007-09-19 씨브이 쎄러퓨틱스, 인코포레이티드 라놀라진 함유 서방성 약제학적 제형물
WO2006119389A2 (en) * 2005-05-03 2006-11-09 Mutual Pharmaceutical Company, Inc. Quinine-containing controlled-release formulations
WO2008080012A1 (en) * 2006-12-21 2008-07-03 Cv Therapeutics, Inc. Reduction of cardiovascular symptoms
CA2677931A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Use of ranolazine for the treatment of cardiovascular diseases
JP2010518171A (ja) * 2007-02-13 2010-05-27 ギリアード・パロ・アルト・インコーポレイテッド 非冠微小血管疾患の処置のためのラノラジンの使用
CA2678319A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Use of ranolazine for the treatment of coronary microvascular diseases
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
US20080233191A1 (en) * 2007-03-22 2008-09-25 Brent Blackburn Use of ranolazine for elevated brain-type natriuretic peptide
EA200971073A1 (ru) * 2007-05-31 2010-08-30 Джилид Пало Альто, Инк. Применение ранолазина при повышенном уровне натрийуретического пептида мозгового типа
AU2009212254A1 (en) * 2008-02-06 2009-08-13 Cv Therapeutics, Inc. Use of Ranolazine for treating pain
JP2012502047A (ja) * 2008-09-04 2012-01-26 ギリアード サイエンシーズ, インコーポレイテッド 心房細動を治療する方法
US20100113514A1 (en) 2008-10-30 2010-05-06 Gilead Palo Alto, Inc. Fused heterocyclic compounds as ion channel modulators
MX2011012140A (es) * 2009-05-14 2012-02-28 Gilead Sciences Inc Ranolazina para el tratamiento de problemas del snc.
WO2014037832A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment of epilepsy and neurological diseases
AU2013257742A1 (en) 2012-05-07 2014-11-27 Cellixbio Private Limited Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
CA2872975A1 (en) 2012-05-07 2013-11-14 Cellixbio Private Limited Compositions and methods for the treatment of neurological disorders
US9399634B2 (en) 2012-05-07 2016-07-26 Cellix Bio Private Limited Compositions and methods for the treatment of depression
US9266823B2 (en) 2012-05-08 2016-02-23 Cellix Bio Private Limited Compositions and methods for the treatment of parkinson's disease
WO2013167992A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of inflammatory disorders
WO2013168025A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of blood clotting disorders
WO2013167991A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic disorders
US9434704B2 (en) 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
US9242939B2 (en) 2012-05-10 2016-01-26 Cellix Bio Private Limited Compositions and methods for the treatment of respiratory disorders
US9499527B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of familial amyloid polyneuropathy
WO2013168033A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neurologic diseases
WO2013168004A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of fibromyalgia pain
US9573927B2 (en) 2012-05-10 2017-02-21 Cellix Bio Private Limited Compositions and methods for the treatment of severe pain
WO2013167999A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurologic diseases
US9394288B2 (en) 2012-05-10 2016-07-19 Cellix Bio Private Limited Compositions and methods for the treatment of asthma and allergy
US9315478B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9339484B2 (en) 2012-05-10 2016-05-17 Cellix Bio Private Limited Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
WO2013168002A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological conditions
WO2013168011A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of chronic pain
SG11201407318UA (en) 2012-05-10 2014-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of metabolic syndrome
WO2013168001A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
US9434729B2 (en) 2012-05-23 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
CA2873096A1 (en) 2012-05-23 2013-11-28 Cellixbio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
JP2015518855A (ja) 2012-05-23 2015-07-06 セリックスビオ プライヴェート リミテッド 粘膜炎の治療のための組成物および方法
US9492409B2 (en) 2012-05-23 2016-11-15 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9227974B2 (en) 2012-05-23 2016-01-05 Cellex Bio Private Limited Compositions and methods for the treatment of respiratory disorders
SG11201407322QA (en) 2012-05-23 2014-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of multiple sclerosis
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
US9187427B2 (en) 2012-08-03 2015-11-17 Cellix Bio Private Limited N-substituted nicotinamide compounds and compositions for the treatment migraine and neurologic diseases
WO2014027262A2 (en) * 2012-08-14 2014-02-20 Mahesh Kandula Compositions and methods for the treatment angina and cardiovascular conditions
US9624168B2 (en) 2012-09-06 2017-04-18 Cellix Bio Private Limited Compositions and methods for the treatment inflammation and lipid disorders
SG11201407325YA (en) 2012-09-08 2014-12-30 Cellix Bio Private Ltd Compositions and methods for treatment of inflammation and lipid disorders
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
CA2914461A1 (en) 2013-06-04 2014-12-11 Cellixbio Private Limited Compositions and methods for the treatment of diabetes and pre-diabetes
CN105611931A (zh) * 2013-08-01 2016-05-25 吉利德科学公司 治疗长qt综合征的化合物和方法
WO2016110865A1 (en) 2015-01-06 2016-07-14 Cellix Bio Private Limited Compositions and methods for the treatment of inflammation and pain
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
WO2016046835A1 (en) 2014-09-26 2016-03-31 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological disorders
CN107207403A (zh) 2014-09-29 2017-09-26 塞尔利克斯生物私人有限公司 用于治疗多发性硬化的组合物和方法
SG11201703369WA (en) 2014-10-27 2017-05-30 Cellix Bio Private Ltd Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
KR101617683B1 (ko) 2015-01-09 2016-05-03 연세대학교 산학협력단 부정맥 치료제 효과 평가 시스템 및 방법
TW201717919A (zh) 2015-07-02 2017-06-01 國際藥品股份公司 雷諾多重壓縮錠劑
WO2018001582A1 (en) 2016-06-30 2018-01-04 Interquim, S.A. Ranolazine multiple compressed tablets

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) * 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4567264A (en) 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
US5364620A (en) * 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) * 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) * 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4902514A (en) * 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
EP0714660B1 (en) * 1989-06-23 2002-09-04 Syntex (U.S.A.) LLC Ranolazine and related piperazines for protecting skeletal muscles
JPH03141258A (ja) * 1989-10-25 1991-06-17 Kowa Co 新規なピペラジン誘導体
DE69429524T2 (de) * 1993-09-24 2002-08-08 Univ British Columbia Aminocyclohexylester und ihre anwendung
US6303607B1 (en) 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
US6528511B2 (en) * 2000-02-18 2003-03-04 Cv Therapeutics, Inc. Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure
US6677336B2 (en) * 2000-02-22 2004-01-13 Cv Therapeutics, Inc. Substituted piperazine compounds
KR100518046B1 (ko) * 2000-05-19 2005-10-04 아밀린 파마슈티칼스, 인크. Glp-1을 사용한 급성 관상동맥 증후군의 치료
US20020052377A1 (en) * 2000-07-21 2002-05-02 Wolff Andrew A. Method for treating angina
US6573264B1 (en) * 2000-10-23 2003-06-03 Cv Therapeutics, Inc. Heteroaryl alkyl piperazine derivatives
US20080109040A1 (en) * 2002-04-04 2008-05-08 Luiz Belardinelli Method of treating arrhythmias
US20030220344A1 (en) * 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias

Also Published As

Publication number Publication date
CN100548300C (zh) 2009-10-14
EP1490066A1 (en) 2004-12-29
DK1490066T3 (da) 2008-10-13
EP2198866A1 (en) 2010-06-23
DK1930007T3 (da) 2010-08-30
CA2481192A1 (en) 2003-10-23
PT1930007E (pt) 2010-08-17
CN1646127A (zh) 2005-07-27
ATE397932T1 (de) 2008-07-15
EP1490066B1 (en) 2008-06-11
CA2481192C (en) 2012-07-03
JP4608217B2 (ja) 2011-01-12
US20030220344A1 (en) 2003-11-27
AU2009201065B2 (en) 2011-07-21
NO330953B1 (no) 2011-08-22
ES2304507T3 (es) 2008-10-16
AU2011202135A1 (en) 2011-05-26
AU2009201065A1 (en) 2009-04-09
CY1110400T1 (el) 2015-04-29
AU2003230810B2 (en) 2009-02-26
MXPA04009637A (es) 2005-07-14
WO2003086401A1 (en) 2003-10-23
ATE470445T1 (de) 2010-06-15
IL197406A0 (en) 2011-07-31
NO20044783L (no) 2004-11-03
HK1120390A1 (en) 2009-04-03
JP2005528393A (ja) 2005-09-22
SI1490066T1 (sl) 2008-10-31
AU2003230810A1 (en) 2003-10-27
SI1930007T1 (sl) 2010-08-31
EP1930007B1 (en) 2010-06-09
US20100004255A1 (en) 2010-01-07
DE60321550D1 (de) 2008-07-24
EP1930007A1 (en) 2008-06-11
KR20100119804A (ko) 2010-11-10
KR20040099395A (ko) 2004-11-26
CN101843619A (zh) 2010-09-29
NZ535610A (en) 2006-05-26
ES2345573T3 (es) 2010-09-27
DE60332975D1 (de) 2010-07-22

Similar Documents

Publication Publication Date Title
IL197406A0 (en) Use of ranolazine for the preparation of a medicament for the treatment of arrhythmias
AU2002232523A1 (en) Pacing methods and devices for treating cardiac arrhythmias and fibrillation
AU8880701A (en) Cardiac arrhythmia treatment methods
EP1803485A3 (en) Method for discriminating between ventricular and supraventricular arrhythmias
WO2002003872A3 (en) Application of photochemotherapy for the treatment of cardiac arrhythmias
IL183852A0 (en) New oxabispidine compounds useful in the treatment of cardiac arrhythmias
WO2004062479A3 (en) Non-invasive heart treatment device
AU2002321105A1 (en) Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis
IL157016A0 (en) Atrial ablation catheter and method for treating atrial fibrillation
ZA200603593B (en) Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias
EP1635801A4 (en) METHODS OF TREATMENT AND PREVENTION OF CARDIAC ARRHYTHMIA
WO2004080421A3 (en) Improved antitumoral treatments
MXPA03002679A (es) Nuevo compuesto de oxabispidina util en el tratamiento de arritmias cardiacas.
EE200300495A (et) 3,7-diasabitsüklo[3.3.1]preparaadid, nende valmistamise meetod ja nimetatud preparaatide kasutaminesüdame arütmiate profülaktikas või ravis
WO2004037167A3 (en) Methods of treating dry eye disease with lantibiotics
WO2002062204A3 (en) Methods for diagnosing and treating heart disease
MXPA02012942A (es) Compuestos nuevos de bispidina y su uso en el tratamiento de arritmias cardiacas.
CA2481005A1 (en) Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and radiotherapy
HK1045520A1 (zh) 用於治療心臟心律不齊的雙哌啶類化合物
PL353794A1 (en) New bispidine compounds useful in the treatment of cardiac arrhythmias
AU2003249999A8 (en) 1,4,7,10-tetraazacyclododecanes as modulators of the guanine-binding protein for treating tumours
CY1115214T1 (el) Η χρηση της ρανολαζινης για την παρασκευη ενος φαρμακου για την θεραπεια των αρρυθμιων
AU2003265321A8 (en) Treatments and methods for the treatment, diagnosis and prophylaxis
PL357102A1 (en) New bispidine compounds useful in the treatment of cardiac arrhythmias
AU2002345119A1 (en) Wood treatment solution and process for improving the preservation of wood